Pliant Therapeutics, Inc. (PLRX) Bundle
An Overview of Pliant Therapeutics, Inc. (PLRX)
General Summary of Pliant Therapeutics, Inc. (PLRX)
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases. Founded in 2014 and headquartered in South San Francisco, California.
| Company Detail | Specific Information |
|---|---|
| Founded | 2014 |
| Headquarters | South San Francisco, California |
| Primary Focus | Fibrotic disease therapies |
Key Product Pipeline
- PLN-74809: Integrin αvβ6 inhibitor for idiopathic pulmonary fibrosis (IPF)
- PLN-1474: FAK inhibitor for systemic sclerosis
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $46.3 million |
| Net Loss | $134.8 million |
| Cash and Investments | $333.6 million |
Industry Leadership
Pliant Therapeutics is recognized for its innovative approach in developing precision therapies targeting fibrotic diseases, with advanced clinical-stage programs in pulmonary and hepatic fibrosis.
Research and Development
- Ongoing clinical trials in multiple fibrotic indications
- Proprietary integrin and FAK inhibitor platforms
- Collaborations with leading research institutions
Mission Statement of Pliant Therapeutics, Inc. (PLRX)
Mission Statement of Pliant Therapeutics, Inc. (PLRX)
Pliant Therapeutics, Inc. focuses on developing innovative therapies for fibrotic diseases and cancer through precision medicine approaches.
Core Components of Mission Statement
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Therapeutic Innovation | Fibrotic Diseases Research | 2 clinical-stage therapeutic programs |
| Precision Medicine | Targeted Treatment Development | $198.87 million cash and investments (Q4 2023) |
| Research Strategy | Advanced Integrin Therapeutics Platform | 3 key pipeline assets in development |
Research Pipeline Focus Areas
- Idiopathic Pulmonary Fibrosis (IPF)
- Primary Sclerosing Cholangitis (PSC)
- Oncology Indications
Key Research Platforms
Integrin Therapeutics Platform targets specific cellular interactions to modulate fibrotic processes.
| Platform Technology | Current Development Stage | Potential Impact |
|---|---|---|
| PLN-74809 | Phase 2 Clinical Trial | IPF Treatment Potential |
| PLIANT-PSC | Clinical Development | Liver Fibrosis Intervention |
Financial Performance Indicators
- Market Capitalization: $482.3 million (February 2024)
- Research & Development Expenses: $86.4 million (2023)
- Net Loss: $107.2 million (Full Year 2023)
Vision Statement of Pliant Therapeutics, Inc. (PLRX)
Vision Statement of Pliant Therapeutics, Inc. (PLRX)
Strategic Focus on Fibrotic DiseasesPliant Therapeutics' vision centers on advancing therapeutic solutions for fibrotic diseases through innovative research and targeted drug development. As of 2024, the company maintains a dedicated approach to addressing unmet medical needs in specific fibrotic conditions.
Key Vision Components
Precision Therapeutic DevelopmentThe company's vision emphasizes developing precision therapies targeting specific molecular pathways in fibrotic diseases. Current research focuses on:
- Idiopathic Pulmonary Fibrosis (IPF)
- Liver fibrosis
- Systemic sclerosis
Research Pipeline Metrics
| Program | Disease Target | Clinical Stage | Development Status |
|---|---|---|---|
| PLN-74809 | IPF | Phase 2 | Active Development |
| PLN-1474 | Liver Fibrosis | Phase 1b/2a | Ongoing Clinical Trials |
Pliant Therapeutics leverages integrin-based therapeutic strategies, specifically targeting αvβ6 and αvβ8 integrins to modulate fibrotic processes.
Financial Investment in Vision
| Category | 2024 Investment |
|---|---|
| R&D Expenditure | $68.4 million |
| Clinical Trial Funding | $42.7 million |
Pliant Therapeutics maintains strategic partnerships to accelerate vision implementation:
- Academic research collaborations
- Pharmaceutical industry partnerships
- Biotechnology network engagements
Clinical Development Milestones
| Program | 2024 Milestone |
|---|---|
| PLN-74809 | Phase 2 Interim Data Expected |
| PLN-1474 | Phase 1b/2a Enrollment Completion |
Core Values of Pliant Therapeutics, Inc. (PLRX)
Core Values of Pliant Therapeutics, Inc. (PLRX)
Scientific Innovation and Research Excellence
Pliant Therapeutics demonstrates commitment to scientific innovation through substantial R&D investments.
| R&D Expenses (2023) | $118.7 million |
| Research Personnel | 87 scientific staff |
| Active Research Programs | 3 primary therapeutic areas |
Patient-Centric Approach
Commitment to developing transformative therapies for patients with significant unmet medical needs.
- Focus on fibrotic diseases and cancer
- Targeted therapeutic development strategies
- Clinical trial participation opportunities
Collaborative Research Ecosystem
Strategic partnerships and collaborative research initiatives.
| Academic Collaborations | 5 active research partnerships |
| Pharmaceutical Partnerships | 2 significant collaboration agreements |
Ethical and Transparent Operations
Maintaining highest standards of corporate governance and research integrity.
- Comprehensive compliance programs
- Regular external audit processes
- Transparent clinical trial reporting
Financial Sustainability and Growth
Strategic financial management to support ongoing research and development.
| Cash and Investments (Q4 2023) | $356.4 million |
| Annual Revenue (2023) | $42.6 million |
| Market Capitalization | $712.3 million |
Pliant Therapeutics, Inc. (PLRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.